MT-3995 Middle

DRUG2 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Diabetic Nephropathy

Phase 2

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

CompletedNCT02517320

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2015-07-31End: 2017-01-31Updated: 2017-03-03

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

CompletedNCT02676401

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2016-02-29Updated: 2017-09-18

Related Papers

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.

2020-09-2464 citations